In order to ensure that medicinal products have the appropriate standards of quality, safety and efficacy and to protect public health, manufacturers of an active substance should communicate without delay any changes which may affect the quality of the active substance to manufacturers of medicinal products using the active substance.
Recital 8, Commission Delegated Regulation (EU) No 1252/2014 of 28 May 2014 supplementing Directive…
In forcesince 28 May 2014